Please login to the form below

FALCON trial of fulvestrant for advanced breast cancer

The Phase III FALCON trial compared fulvestrant to anastrozole for hormone receptor-positive advanced breast cancer.


Summary/transcript

Prof. Matthew Ellis from the Baylor College of Medicine presented the trial and talked to us about its design, the results and implications. In the interview, he explains that the study was designed to address the question if there is an optimal first-line endocrine therapy for patients with hormone receptor-positive advanced breast cancer who had not been treated with a hormonal agent before.

The primary endpoint of the study was progression-free survival (PFS); Prof. Ellis highlights that “patients on fulvestrant stayed on the drug in response approximately three months longer than patients on anastrozole” (16.6 months vs 13.8 months).

Prof. Ellis further points out that the results were statistically significant but the question is, if they are clinically significant. He explains that these kinds of differences as observed in this trial, have driven changes in clinical practice before as in the case of tamoxifen and aromatase inhibitors.

If you would like to discover how we can leverage our network of relationships and understanding of the oncology landscape and stakeholders, to shape content and amplify messages across relevant audiences, channels and communities please contact either Stephen Dunn or Charlie Grieve on 020 7291 5070, we’d be delighted to hear from you.

17th November 2016

Share

Tags

Company Details

Brandcast Health

+44 (0)20 7291 5070

Contact Website

Address:
16-17 Little Portland Street
London
W1W 8BP

Latest content on this profile

Day 2 Round-up from the Giant Health Event
Robin gives a quick overview of day 2 of the Giant Health Event.
Brandcast Health
Why patient education is important in oncology
We talked to Dr Bettina Ryll of Melanoma Patient Network Europe about changes in melanoma treatment and how the added complexity of new treatments has changed how patients need to be informed.
Brandcast Health
CABOSUN trial of cabozantinib – could it change how we treat frontline renal-cell carcinoma?
In the CABOSUN trial, cabozantinib was compared to sunitinib in treatment naive poor and intermediate risk renal-cell carcinoma (RCC) patients.
Brandcast Health
No surprises: results from the ENGOT-OV16/NOVA trial of niraparib in ovarian cancer
The ENGOT-OV16/NOVA trial of niraparib was a randomized, double-blinded placebo study with women with relapsed platinum-sensitive high-grade ovarian cancer.
Brandcast Health
FALCON trial of fulvestrant for advanced breast cancer
The Phase III FALCON trial compared fulvestrant to anastrozole for hormone receptor-positive advanced breast cancer.
Brandcast Health
Overview of the GIANT Health Event
Shafi Ahmed, PhD, FRCS, Director of Virtual Medics and Medical and GIANT Event Co-chair, provides an overview of the GIANT Health Event.
Brandcast Health